FINWIRES · TerminalLIVE
FINWIRES

Top Midday Stories: GE Vernova Shares Gain on Strong Q1 Earnings, Guidance; Vertiv Lifts Guidance After Q1 EPS, Revenue Beats, Shares Fall

-- All three major US stock indexes were up in late-morning trading Wednesday following reports of Iranian attacks on vessels in the Strait of Hormuz and President Donald Trump's extension of the ceasefire between the warring nations.

In company news, GE Vernova (GEV) reported Q1 earnings Wednesday of $17.44 per share, up from $0.91 a year earlier. Total Q1 revenue was $9.34 billion, up from $8.03 billion a year ago and above the FactSet consensus analyst estimate of $9.25 billion. For 2026, the company said it expects revenue of about $44.5 billion to $45.5 billion, up from its previous outlook of $44 billion to $45 billion and compared to the FactSet consensus of $44.66 billion. GE Vernova shares were up 12.4% around midday.

Vertiv (VRT) reported Q1 adjusted earnings Wednesday of $1.17 per diluted share, up from $0.64 a year earlier and above the FactSet consensus of $1.00. First-quarter revenue was $2.65 billion, up from $2.04 billion a year ago and above the FactSet consensus of $2.64 billion. For Q2, the company said it expects adjusted EPS of $1.37 to $1.43 on revenue of $3.25 billion to $3.45 billion. Analysts polled by FactSet expect $1.43 and $3.40 billion, respectively. For full-year 2026, Vertiv said it expects adjusted EPS of $6.30 to $6.40, up from its previous outlook of $5.97 to $6.07 and above the FactSet consensus of $6.12. Vertiv expects full-year revenue to be $13.50 billion to $14.00 billion, up from its previous guidance of $13.25 billion to $13.75 billion and compared to the FactSet consensus of $13.63 billion. Vertiv shares were down 2.6%.

Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at over $8 billion, Reuters reported Wednesday, citing people familiar with the matter. Merck shares were down 0.2%, while Inhibrx shares were up 31.9%.

Boeing (BA) reported a Q1 core loss Wednesday of $0.20 per share, narrowing from a loss of $0.49 a year earlier and compared to the FactSet consensus estimate of a loss of $0.68. First-quarter revenue was $22.22 billion, up from $19.50 billion a year ago and above the FactSet consensus of $21.85 billion. Cash outflow for the quarter was $1.45 billion, narrowing from $2.29 billion a year ago, and the company said Q1 deliveries increased 10% to 143 planes. Boeing shares were up 5.4%.

Alphabet's (GOOG, GOOGL) Google Cloud is launching a $750 million fund to help consulting firms like Accenture (ACN), McKinsey and Deloitte get their clients to use agentic AI software, Bloomberg reported Wednesday, citing an emailed statement and an interview with a company official. Alphabet's Class C and Class A shares were up 1.5% and 1.6%, respectively. Accenture shares were down 1.9%.

Philip Morris International (PM) reported Q1 adjusted earnings Wednesday of $1.96 per diluted share, up from $1.69 a year earlier and above the FactSet consensus of $1.83. Net Q1 revenue was $10.15 billion, up from $9.30 billion ay ear ago and above the FactSet consensus of $9.91 billion. For Q2, Philip Morris said it expects adjusted EPS of $2.02 to $2.07, below the FactSet consensus of $2.12. For full-year 2026, the company said it expects adjusted EPS of $8.36 to $8.51, compared to the FactSet consensus of $8.38. Philip Morris shares were up 7%.

Boston Scientific (BSX) reported Q1 adjusted earnings Wednesday of $0.80 per share, up from $0.75 a year earlier and above the FactSet consensus of $0.79. First-quarter net sales were $5.20 billion, up from $4.66 billion a year ago and above the FactSet consensus of $5.17 billion. For Q2, Boston Scientific said it expects adjusted EPS of $0.82 to $0.84 and net sales growth of 5.5% to 7.5%. Analysts polled by FactSet expect adjusted EPS of $0.86. For full-year 2026, the company said it expects adjusted EPS of $3.34 to $3.41, down from its prior outlook of $3.43 to $3.49 and below the FactSet consensus of $3.45. Full-year net sales are now expected to grow about 7.0% to 8.5%, down from the company's previous guidance of 10.5% to 11.5% growth. Shares of the company were up 8.4%.

AT&T (T) reported Q1 earnings Wednesday of $0.54 per diluted share, down from $0.61 a year earlier and below the FactSet consensus of $0.55. First-quarter operating revenue was $31.51 billion, up from $30.63 billion a year ago and above the FactSet consensus of $31.25 billion. AT&T shares were down 1.8%.

Price: $1119.35, Change: $+128.05, Percent Change: +12.92%

相关文章

Asia

受以色列和黎巴嫩停火延长三周消息提振,韩国股市小幅高开。

受以色列和黎巴嫩宣布将停火延长三周的提振,韩国股市周五小幅高开。此前,双方于周四在白宫举行了会谈。 韩国综合股价指数(KOSPI)小幅上涨,开盘报6496.10点。韩国创业板指数(KOSDAQ)上涨0.2%,即2.11点,开盘报1176.42点。 此次会谈标志着以色列和黎巴嫩数十年来首次直接外交接触,对于自1948年以来一直处于战争状态的两国而言,这无疑是一项重大突破。 在伊朗问题上,美国总统特朗普表示,他不想在与伊朗达成协议的问题上操之过急。他表示,自己没有结束冲突的压力,而是专注于与伊朗达成尽可能好的协议。 特朗普声称美国完全控制着霍尔木兹海峡,并表示一旦伊朗达成协议,美国将获得通行权。他还表示,希望在停火期间限制德黑兰的石油收入。 特朗普警告说,如果伊朗拒绝谈判,美国可能会采取军事行动升级局势。

$^KOSDAQ$^KS11
Asia

Eoptolink Technology 2025年利润预计增长236%;股价下跌8%

亿光科技(深圳证券交易所代码:300502)公布2025财年净利润为95.3亿元人民币,较上年同期的28.4亿元人民币增长236%。 根据周五提交给深圳证券交易所的文件,每股收益从4.00元人民币增至9.57元人民币。 营收同比增长187%,从86.4亿元人民币增至248亿元人民币。 这家光收发模块制造商的股价在近期交易中下跌了8%。

$SHE:300502
Asia

新西兰证券交易所午间行业板块更新:耐用消费品板块飙升,科技服务板块表现疲软

周五,新西兰证券交易所消费品板块涨幅最大,上涨近2%。 KMD Brands(NZE:KMD,ASX:KMD)股价在近期交易中上涨近2%。 另一方面,科技服务板块表现疲软,下跌超过3%。 Gentrack Group(NZE:GTK,ASX:GTK)股价在近期交易中下跌近7%。

$^NZ50$ASX:GTK$ASX:KMD$NZE:GTK$NZE:KMD